Yahoo Finance

Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced today the European Society ...
Yahoo Finance

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company’) today announced data from its Phase 1/2 clinical study of CRB-701 ...
ascopubs.org

Phase I dose-escalation study of the next-generation nectin-4 targeting antibody–drug conjugate CRB-701 (SYS6002) in US and UK patients with urothelial cancer and other solid ...

A phase I first-in-human clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in therapy-resistant non-muscle-invasive bladder cancer (NMIBC). This is an ASCO Meeting Abstract from the ...
Yale Daily News

After CRB nominees rejected, questions remain

After five of the 11 nominees for the Civilian Review Board were nearly unanimously voted down, community members have mixed feelings regarding the process of the board’s establishment. Last January, ...
Business Insider

Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- ...